Source Fact: Financial Supervisory Service DART / 2025-07-03
Disclosure Type: Ruling on Lawsuit (Claim Over a Certain Amount)
💡 3-Second Summary
Celltrion has been ordered to pay approximately KRW 12.7 billion in the first instance of its COVID-19 diagnostic kit contract dispute with Humasis. The company announced its intention to file an appeal once the official written judgment is delivered.
📊 1. [Key Disclosure Details & Major Figures]
- Case Name: Product Payment, etc. (Suwon District Court Anyang Branch, Case No. 2023Gahap100211)
- Plaintiff: Humasis Co., Ltd.
- First Instance Judgment (Amount Defendant Celltrion is Ordered to Pay to Plaintiff Humasis):
- Judgment Amount: KRW 12,710,724,105 (Approx. KRW 12.7B, representing 0.07% of Celltrion’s equity)
- Breakdown:
- USD 2,094,300 (Approx. KRW 2.85B based on the base rate of USD/KRW 1,359.40 on the judgment date of July 3, 2025) plus delinquency interest
- KRW 9,863,732,685 plus delinquency interest
- Delinquency Interest Rate: 6% per annum up to July 3, 2025, and 12% per annum thereafter until fully paid
- Litigation Costs Allocation: 90% to be borne by Plaintiff (Humasis) and 10% by Defendant (Celltrion)
- Date of Ruling & Confirmation: July 03, 2025 (Based on the date of the court’s verbal announcement; the written judgment has not yet been formally received by Celltrion)
- Future Action: Celltrion will issue an amended disclosure upon receiving the formal written judgment and intends to actively appeal the ruling through standard legal channels.
📈 2. [Expert Perspective: What This Means for Investors]
This filing details the first-instance court ruling concerning outstanding supply payments and damages stemming from a pandemic-era COVID-19 diagnostic kit joint business agreement between Celltrion and Humasis. The court-ordered payment of approximately KRW 12.7 billion accounts for only 0.07% of Celltrion’s consolidated equity (approx. KRW 17.58T). Consequently, this ruling is highly unlikely to pose any immediate or material risk to the company’s robust balance sheet or general financial liquidity.
Investors should be careful to separate the principal payment obligation from the court-ordered allocation of litigation costs. Although Celltrion’s portion of litigation costs was limited to 10%, this cost allocation only applies to administrative fees and court expenses incurred during the trial; it does not offset, reduce, or alter the principal payment obligation of KRW 12.7 billion. Furthermore, because Celltrion has explicitly declared its intention to appeal, the current judgment is not yet finalized, and the final cash outflow will depend entirely on the subsequent rulings of the higher courts.
📝 Editor’s Comment (by K-STOCK Editor)
The pandemic-era legacy conflict regarding the termination of the COVID-19 diagnostic kit business has yielded its first judicial decision. While the court ordered Celltrion to pay approximately KRW 12.7 billion, the financial impact remains highly manageable given the scale of the company’s assets. However, Celltrion’s planned appeal suggests that a final resolution of this dispute is still far off.
For global investors, the primary variable to monitor during this prolonged legal process is the potential increase in interest expense. Under the court’s ruling, delinquency interest of 12% per annum will accrue on the principal amount after the judgment date until the settlement is finalized. Therefore, the duration of the appeal and the final appellate court ruling will dictate the ultimate size of the financial liability.
Additionally, investors should keep an eye on whether and to what extent Celltrion chooses to set aside litigation provisions or reserves in its upcoming quarterly financial statements. Monitoring these legacy administrative risks in upcoming quarterly reports will be necessary to ensure that any temporary impacts on quarterly earnings are properly accounted for.
📢 Disclaimer & Source
Source: This content has been structured and rewritten based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Inquiries: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
